Dupilumab decreases concomitant therapy use in adults with atopic dermatitis in clinical practice: Subgroup analysis of Black/African American population from RELIEVE-AD

Raj Chovatiya,1 Jingdong Chao,2 Chien-Chia Chuang,3 Min Yang,4 Brad Shumel,2 Bruno Martins,4 Gaelle Bégo-Le-Bagousse,5 Debra Sierka,3 Dimitri Delevry2

1Northwestern University Feinberg School of Medicine, Chicago, IL, USA; 2Regeneron Pharmaceuticals Inc, Tarrytown, NY, USA; 3Sanofi, Cambridge, MA, USA; 4Analysis Group, Inc, Boston, MA, USA; 5Sanofi, Chilly-Mazarin, France

BACKGROUND
- Dupilumab is a fully human anti-interleukin-4 receptor α monoclonal antibody approved for patients aged ≥6 months with moderate-to-severe atopic dermatitis (AD) inadequately controlled by topical therapies1,2
- The safety and efficacy of dupilumab have been demonstrated in phase 3 clinical trials3-11
- A prospective, real-world, longitudinal patient survey study, RELIEVE-AD, demonstrated that dupilumab treatment decreases concomitant medication use in adults with moderate-to-severe AD12
- A subgroup analysis of concomitant AD medication use was conducted in Black/African American adults with AD from the RELIEVE-AD study

OBJECTIVE
- To evaluate the real-world impact of dupilumab on concomitant AD therapy use from the perspective of Black/African American patients, a population in which clinical study data are limited

METHODS
- In the RELIEVE-AD study, adults with moderate-to-severe AD were identified through the US dupilumab patient support program and invited to participate in an online survey before (baseline) and after dupilumab initiation at Months 1, 2, 3, 6, 9, and 1212
- Based on a 4-week recall, surveys assessed concomitant AD therapy use, including oral/injectable steroids, immunosuppressants, prescription topical medications (steroids, calcineurin inhibitors, crisaborole), and UV light therapy at baseline and throughout 1 year after treatment initiation
- A subgroup analysis of self-reported data from Black/African American population was performed

RESULTS

Patient Characteristics
- Of 64 Black/African American patients completing the baseline survey, 43 provided responses at Month 12, with a survey completion rate of 67.2%.
- Among patients who completed the survey at Month 12 (N = 43), mean age at study initiation was 38.8 years and a majority of patients were female (Table 1)

Concomitant AD Medication Use
- The proportion of patients reporting no concomitant treatment use significantly increased from baseline (7.8%) to Month 12 (30.2%, P<0.05; Figure 1)
- A significant reduction in concomitant AD medication use across all categories from baseline to Month 12 was reported (Figure 2)
  - Use of prescription topical medication decreased from baseline (87.5%) to Month 12 (67.4%, P<0.05)
  - Use of systemic steroids and immunosuppressants reduced from baseline (32.8%) to Month 12 (14.0%, P<0.05)

CONCLUSIONS
- In Black/African American adults with moderate-to-severe AD treated with dupilumab, concomitant AD medication use was significantly reduced in a real-world clinical practice setting
- Interpretation of the results of this subgroup analysis should account for the small sample size and attrition over the study period

Reference:

Presented at the Fall Clinical Dermatology Conference 2023, October 19–22, Las Vegas, NV.